Table 2 |
|||
|
Recently published clinical studies of three leading hemoglobin-based oxygen carriers |
|||
| Product name |
|||
|
|
|||
| Details |
PolyHeme® |
Hemopure® (HBOC-201) |
HemoLink™ (Hb-raffimer) |
|
|
|||
| Company |
Northfield Laboratories (Evanston, IL, USA) |
Biopure Corporation (Cambridge, MA, USA) |
Hemosol Inc. (Ontario, Canada) |
| Indicated use |
Trauma/urgent surgery |
Cardiac surgery |
Coronary artery bypass graft |
| Clinical trial status |
Phase III |
Phase III |
Phase II/III |
| Study design |
Multicenter, randomized, double blind |
Multicenter, randomized, double blind |
Multicenter, randomized, single blind |
| End-point |
Mortality |
Transfusion avoidance |
Transfusion avoidance |
| Major findings |
PolyHeme increased survival |
Hemopure reduced allogeneic red cell transfusion |
HemoLink reduced allogeneic red cell transfusion |
| Current status |
Phase III mortality study |
Filed BLA |
Clinical study suspended pending further analysis |
| Reference |
Gould and coworkers [11] |
Levy and coworkers [12] |
Hill and coworkers [19] |
|
|
|||
|
BLA, Biologic License Application. |
|||
|
Greenburg and Kim Critical Care 2004 8(Suppl 2):S61 doi:10.1186/cc2455 |
|||